all report title image

ALK POSITIVE LUNG CANCER TREATMENT MARKET ANALYSIS

ALK Positive Lung Cancer Treatment Market by Drugs (Crizotinib, Alectinib, Ceritinib, and Brigatinib), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Clinics), and by Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Dec 2024
  • Code : CMI2201
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Regional Analysis

ALK Positive Lung Cancer Treatment Market – Regional Analysis

On the basis of region, the global ALK positive lung cancer treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America region is expected to witness significant growth in the market, owing to increasing number of clinical trials operating in the U.S. For instance, TP Therapeutics, Inc., is undergoing clinical trial for TPX-0005 drug for treating ALK mutations. The study is expected to complete in December 2021.

Asia Pacific region is expected to witness the significant growth in the market, owing to increasing use of tobacco and smoking leading to lung cancer.  According to an article published in Eastern Journal of medical Sciences 2017, lung cancer contributes around 6.8% of all cancers in India, representing the significant burden of lung cancer on country, which is contributing towards the cancer morbidity and mortality.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.